Table 3.
Group | Covariate | Estimate (SD) | p-value |
---|---|---|---|
Placebo | Male | -0.78 (0.14) | <.0001 |
Male*Crav | -0.69 (0.15) | <.0001 | |
Male*NA | 0.54 (0.18) | 0.0022 | |
Lapse | 0.24 (0.24) | 0.3234 | |
Baseline dependence | -0.60 (0.10) | <.0001 | |
| |||
Monotherapy | Male | -0.48 (0.06) | <.0001 |
Male*Crav | -0.50 (0.07) | <.0001 | |
Male*NA | 0.40 (0.07) | <.0001 | |
Lapse | 0.61 (0.11) | <.0001 | |
Baseline dependence | 0.24 (0.03) | <.0001 | |
| |||
Combined therapy | Male | -0.32 (0.06) | <.0001 |
Male*Crav | -0.24 (0.07) | 0.0006 | |
Male*NA | 0.04 (0.09) | 0.6570 | |
Lapse | -0.32 (0.13) | 0.0154 | |
Baseline dependence | 0.14 (0.03) | <.0001 |
This table contains only the coefficient estimates of the model parameters that are assumed to be time-constant, namely, β3, β4, β5, β6, and β7. The inference of the time-varying effects that are of primary interest (i.e., the intercepts, the effects of craving and the effects of negative affect) can be drawn from Fig. 3, Fig. 4 and Fig. 5.